BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Bartolomeis A, Vellucci L, Barone A, Manchia M, De Luca V, Iasevoli F, Correll CU. Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. Pharmacol Ther 2022;236:108236. [PMID: 35764175 DOI: 10.1016/j.pharmthera.2022.108236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tibrewal P, Nair PC, Gregory KJ, Langmead CJ, Chan SKW, Bastiampillai T. Does clozapine treat antipsychotic-induced behavioural supersensitivity through glutamate modulation within the striatum? Mol Psychiatry 2023. [PMID: 36932159 DOI: 10.1038/s41380-023-02026-x] [Reference Citation Analysis]
2 Saraf TS, McGlynn RP, Bhatavdekar OM, Booth RG, Canal CE. FPT, a 2-Aminotetralin, Is a Potent Serotonin 5-HT(1A), 5-HT(1B), and 5-HT(1D) Receptor Agonist That Modulates Cortical Electroencephalogram Activity in Adult Fmr1 Knockout Mice. ACS Chem Neurosci 2022;13:3629-40. [PMID: 36473166 DOI: 10.1021/acschemneuro.2c00574] [Reference Citation Analysis]
3 de Bartolomeis A, De Simone G, Ciccarelli M, Castiello A, Mazza B, Vellucci L, Barone A. Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance. Biomedicines 2022;10. [PMID: 36551939 DOI: 10.3390/biomedicines10123183] [Reference Citation Analysis]
4 de Bartolomeis A, Ciccarelli M, Vellucci L, Fornaro M, Iasevoli F, Barone A. Update on novel antipsychotics and pharmacological strategies for treatment resistant schizophrenia. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2145884] [Reference Citation Analysis]
5 Kane JM, Kinon BJ, Forray C, Such P, Mittoux A, Lemming OM, Hertel P, Howes OD; DayBreak and Debut study investigators. Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension. Schizophr Res 2022;248:271-8. [PMID: 36115192 DOI: 10.1016/j.schres.2022.09.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]